March 7, 2024 02:46 PM ESTUpdated 05:09 PM

Boehringer Ingelheim caps inhaler out-of-pocket costs at $35 after political pressure

Katherine Lewin

News Reporter

After Senate Democrats on the health committee pressed inhaler manufacturers on their high US prices earlier this year, Boehringer Ingelheim said Thursday that it would …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Boehringer Ingelheim caps inhaler out-of-pocket costs at $35 after political pressure

Katherine Lewin

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Boehringer In­gel­heim caps in­haler out-of-pock­et costs at $35 af­ter po­lit­i­cal pres­sure

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Boehringer Ingelheim caps inhaler out-of-pocket costs at $35 after political pressure